Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
AstraZeneca
Dow
Mallinckrodt
Johnson and Johnson

Last Updated: December 8, 2019

DrugPatentWatch Database Preview

CISATRACURIUM BESYLATE Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

When do Cisatracurium Besylate patents expire, and when can generic versions of Cisatracurium Besylate launch?

Cisatracurium Besylate is a drug marketed by Accord Hlthcare, Anda Repository, Fresenius Kabi Usa, Hospira Inc, Jiangsu Hengrui Med, Nanjing King-friend, Sandoz Inc, and Somerset Theraps Llc. and is included in fourteen NDAs.

The generic ingredient in CISATRACURIUM BESYLATE is cisatracurium besylate. There are nine drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the cisatracurium besylate profile page.

Drug patent expirations by year for CISATRACURIUM BESYLATE
Drug Prices for CISATRACURIUM BESYLATE

See drug prices for CISATRACURIUM BESYLATE

Recent Clinical Trials for CISATRACURIUM BESYLATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Mahidol UniversityPhase 4
General Hospital of Ningxia Medical UniversityN/A
Medical University of GrazN/A

See all CISATRACURIUM BESYLATE clinical trials

Pharmacology for CISATRACURIUM BESYLATE
Synonyms for CISATRACURIUM BESYLATE
(1R-cis,1'R-cis)-2,2'-{pentane-1,5-diylbis[oxy(3-oxopropane-3,1-diyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium] bisbenzenesulfonate
(1R-cis,1'R-cis)-Atracurium besylate
(1R,1'R,2R,2'R)-2,2'-((pentane-1,5-diylbis(oxy))bis(3-oxopropane-3,1-diyl))bis(1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium) benzenesulfona
(1R,1'R,2R,2'R)-2,2'-((pentane-1,5-diylbis(oxy))bis(3-oxopropane-3,1-diyl))bis(1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium) benzenesulfonate
(1R,2R,1'R,2'R)-2,2'-{pentane-1,5-diylbis[oxy(3-oxopropane-3,1-diyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium] bisbenzenesulfonate
(1R,2R,1'R,2'R)-atracurium besylate
(1R,2R)-2-(2-Carboxyethyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-veratrylisoquinolinium benzenesulfonate, pentamethylene ester
51 W89
51W89
80YS8O1MBS
96946-42-8
AC1L1XZG
AC1Q22ND
AK546900
AKOS026750111
Atracurium besylate 1R-cis,1R'-cis form
Besilate de cisatracurium
Besilato de cisatracurio
C53H72N2O12.2(C6H5O3S)
C53H72N2O12.2C6H5O3S
CAS-64228-81-5
CCG-221271
CHEBI:3721
CHEMBL1200641
Cisatracurii besilas
Cisatracurium (besylate)
Cisatracurium besilate
Cisatracurium besilate (INN)
Cisatracurium besilate [INN]
Cisatracurium besilate, EuropePharmacopoeia (EP) Reference Standard
Cisatracurium besylate (Nimbex)
Cisatracurium besylate (USAN)
Cisatracurium besylate [USAN:BAN]
Cisatracurium besylate [USAN]
Cisatracurium Besylate Preservative Free
Cisatracurium besylate, United States Pharmacopeia (USP) Reference Standard
cisatracurium besylate(usan)
cisatracurium dibenzenesulfonate
Cisatracurium for peak identification, EuropePharmacopoeia (EP) Reference Standard
Cisatracurium for system suitability, EuropePharmacopoeia (EP) Reference Standard
Cisatracurium-Kation
CS-2471
D00759
DB00565
EX-A2646
FT-0657467
HMS3715P04
HY-13596
Isoquinolinium, 2,2'-(1,5-pentanediylbis(oxy(3-oxo-3,1-propanediyl)))bis(1-((3,4-dimethoxyphenyl)methyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-, dibenzenesulfonate, (1R-(1alpha,2alpha(1'R(sup *),2'R(sup *))))-
KS-00000FXO
LS-178337
MolPort-003-987-490
N769
NCGC00017127-01
Nimbex
Nimbex (TN)
Nimbex Forte
NIMBEX PRESERVATIVE FREE
Nimbium
s2113
SCHEMBL40669
SW222230-1
TL8006016
UNII-40AX66P76P component XXZSQOVSEBAPGS-DONVQRBFSA-L
UNII-80YS8O1MBS
UNII-Y78PS7MEDE component XXZSQOVSEBAPGS-DONVQRBFSA-L
W-60404
XXZSQOVSEBAPGS-DONVQRBFSA-L
Z2216208615
Paragraph IV (Patent) Challenges for CISATRACURIUM BESYLATE
Tradename Dosage Ingredient NDA Submissiondate
NIMBEX INJECTABLE;INJECTION cisatracurium besylate 020551 2009-08-12
NIMBEX PRESERVATIVE FREE INJECTABLE;INJECTION cisatracurium besylate 020551 2009-08-12
NIMBEX PRESERVATIVE FREE INJECTABLE;INJECTION cisatracurium besylate 020551 2009-08-04
NIMBEX INJECTABLE;INJECTION cisatracurium besylate 020551 2009-08-04

US Patents and Regulatory Information for CISATRACURIUM BESYLATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Accord Hlthcare CISATRACURIUM BESYLATE cisatracurium besylate INJECTABLE;INJECTION 205873-001 Jun 16, 2017 DISCN No No   Start Trial   Start Trial   Start Trial
Sandoz Inc CISATRACURIUM BESYLATE PRESERVATIVE FREE cisatracurium besylate INJECTABLE;INJECTION 200154-001 Feb 3, 2012 AP RX No No   Start Trial   Start Trial   Start Trial
Jiangsu Hengrui Med CISATRACURIUM BESYLATE cisatracurium besylate INJECTABLE;INJECTION 209334-001 Aug 30, 2017 AP RX No No   Start Trial   Start Trial   Start Trial
Hospira Inc CISATRACURIUM BESYLATE cisatracurium besylate INJECTABLE;INJECTION 203236-001 Mar 30, 2018 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
McKinsey
Baxter
McKesson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.